Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

Vanessa E. Rees, Deanna S. Deveson Lucas, Carla López-Causapé, Yuling Huang, Tom Kotsimbos, Jürgen B. Bulitta, Murray C. Rees, Adele Barugahare, Anton Y. Peleg, Roger L. Nation, Antonio Oliver, John D. Boyce, Cornelia B. Landersdorfer

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Hypermutable Pseudomonas aeruginosa isolates (hypermutators) have been identified in patients with cystic fibrosis (CF) and are associated with reduced lung function. Hypermutators display a greatly increased mutation rate and an enhanced ability to become resistant to antibiotics during treatment. Their prevalence has been established among patients with CF, but it has not been determined for patients with CF in Australia. This study aimed to determine the prevalence of hypermutable P. aeruginosa isolates from adult patients with CF from a health care institution in Australia and to characterize the genetic diversity and antibiotic susceptibility of these isolates. A total of 59 P. aeruginosa clinical isolates from patients with CF were characterized. For all isolates, rifampin (RIF) mutation frequencies and susceptibility to a range of antibiotics were determined. Of the 59 isolates, 13 (22%) were hypermutable. Whole-genome sequences were determined for all hypermutable isolates. Core genome polymorphisms were used to assess genetic relatedness of the isolates, both to each other and to a sample of previously characterized P. aeruginosa strains. Phylogenetic analyses showed that the hypermutators were from divergent lineages and that hypermutator phenotype was mostly the result of mutations in mutL or, less commonly, in mutS. Hypermutable isolates also contained a range of mutations that are likely associated with adaptation of P. aeruginosa to the CF lung environment. Multidrug resistance was more prevalent in hypermutable than nonhypermutable isolates (38% versus 22%). This study revealed that hypermutable P. aeruginosa strains are common among isolates from patients with CF in Australia and are implicated in the emergence of antibiotic resistance.

Original languageEnglish
Article numbere02538-18
Number of pages11
JournalAntimicrobial Agents and Chemotherapy
Volume63
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • Antibiotic resistance
  • Cystic fibrosis
  • Hypermutation
  • Multidrug resistance
  • Pseudomonas aeruginosa
  • Whole-genome sequencing

Cite this

Rees, Vanessa E. ; Deveson Lucas, Deanna S. ; López-Causapé, Carla ; Huang, Yuling ; Kotsimbos, Tom ; Bulitta, Jürgen B. ; Rees, Murray C. ; Barugahare, Adele ; Peleg, Anton Y. ; Nation, Roger L. ; Oliver, Antonio ; Boyce, John D. ; Landersdorfer, Cornelia B. / Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. In: Antimicrobial Agents and Chemotherapy. 2019 ; Vol. 63, No. 4.
@article{101a8ad2dd7a4887874036885c2198b9,
title = "Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia",
abstract = "Hypermutable Pseudomonas aeruginosa isolates (hypermutators) have been identified in patients with cystic fibrosis (CF) and are associated with reduced lung function. Hypermutators display a greatly increased mutation rate and an enhanced ability to become resistant to antibiotics during treatment. Their prevalence has been established among patients with CF, but it has not been determined for patients with CF in Australia. This study aimed to determine the prevalence of hypermutable P. aeruginosa isolates from adult patients with CF from a health care institution in Australia and to characterize the genetic diversity and antibiotic susceptibility of these isolates. A total of 59 P. aeruginosa clinical isolates from patients with CF were characterized. For all isolates, rifampin (RIF) mutation frequencies and susceptibility to a range of antibiotics were determined. Of the 59 isolates, 13 (22{\%}) were hypermutable. Whole-genome sequences were determined for all hypermutable isolates. Core genome polymorphisms were used to assess genetic relatedness of the isolates, both to each other and to a sample of previously characterized P. aeruginosa strains. Phylogenetic analyses showed that the hypermutators were from divergent lineages and that hypermutator phenotype was mostly the result of mutations in mutL or, less commonly, in mutS. Hypermutable isolates also contained a range of mutations that are likely associated with adaptation of P. aeruginosa to the CF lung environment. Multidrug resistance was more prevalent in hypermutable than nonhypermutable isolates (38{\%} versus 22{\%}). This study revealed that hypermutable P. aeruginosa strains are common among isolates from patients with CF in Australia and are implicated in the emergence of antibiotic resistance.",
keywords = "Antibiotic resistance, Cystic fibrosis, Hypermutation, Multidrug resistance, Pseudomonas aeruginosa, Whole-genome sequencing",
author = "Rees, {Vanessa E.} and {Deveson Lucas}, {Deanna S.} and Carla L{\'o}pez-Causap{\'e} and Yuling Huang and Tom Kotsimbos and Bulitta, {J{\"u}rgen B.} and Rees, {Murray C.} and Adele Barugahare and Peleg, {Anton Y.} and Nation, {Roger L.} and Antonio Oliver and Boyce, {John D.} and Landersdorfer, {Cornelia B.}",
year = "2019",
month = "4",
day = "1",
doi = "10.1128/AAC.02538-18",
language = "English",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "1098-6596",
publisher = "American Society for Microbiology",
number = "4",

}

Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia. / Rees, Vanessa E.; Deveson Lucas, Deanna S.; López-Causapé, Carla; Huang, Yuling; Kotsimbos, Tom; Bulitta, Jürgen B.; Rees, Murray C.; Barugahare, Adele; Peleg, Anton Y.; Nation, Roger L.; Oliver, Antonio; Boyce, John D.; Landersdorfer, Cornelia B.

In: Antimicrobial Agents and Chemotherapy, Vol. 63, No. 4, e02538-18, 01.04.2019.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia

AU - Rees, Vanessa E.

AU - Deveson Lucas, Deanna S.

AU - López-Causapé, Carla

AU - Huang, Yuling

AU - Kotsimbos, Tom

AU - Bulitta, Jürgen B.

AU - Rees, Murray C.

AU - Barugahare, Adele

AU - Peleg, Anton Y.

AU - Nation, Roger L.

AU - Oliver, Antonio

AU - Boyce, John D.

AU - Landersdorfer, Cornelia B.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Hypermutable Pseudomonas aeruginosa isolates (hypermutators) have been identified in patients with cystic fibrosis (CF) and are associated with reduced lung function. Hypermutators display a greatly increased mutation rate and an enhanced ability to become resistant to antibiotics during treatment. Their prevalence has been established among patients with CF, but it has not been determined for patients with CF in Australia. This study aimed to determine the prevalence of hypermutable P. aeruginosa isolates from adult patients with CF from a health care institution in Australia and to characterize the genetic diversity and antibiotic susceptibility of these isolates. A total of 59 P. aeruginosa clinical isolates from patients with CF were characterized. For all isolates, rifampin (RIF) mutation frequencies and susceptibility to a range of antibiotics were determined. Of the 59 isolates, 13 (22%) were hypermutable. Whole-genome sequences were determined for all hypermutable isolates. Core genome polymorphisms were used to assess genetic relatedness of the isolates, both to each other and to a sample of previously characterized P. aeruginosa strains. Phylogenetic analyses showed that the hypermutators were from divergent lineages and that hypermutator phenotype was mostly the result of mutations in mutL or, less commonly, in mutS. Hypermutable isolates also contained a range of mutations that are likely associated with adaptation of P. aeruginosa to the CF lung environment. Multidrug resistance was more prevalent in hypermutable than nonhypermutable isolates (38% versus 22%). This study revealed that hypermutable P. aeruginosa strains are common among isolates from patients with CF in Australia and are implicated in the emergence of antibiotic resistance.

AB - Hypermutable Pseudomonas aeruginosa isolates (hypermutators) have been identified in patients with cystic fibrosis (CF) and are associated with reduced lung function. Hypermutators display a greatly increased mutation rate and an enhanced ability to become resistant to antibiotics during treatment. Their prevalence has been established among patients with CF, but it has not been determined for patients with CF in Australia. This study aimed to determine the prevalence of hypermutable P. aeruginosa isolates from adult patients with CF from a health care institution in Australia and to characterize the genetic diversity and antibiotic susceptibility of these isolates. A total of 59 P. aeruginosa clinical isolates from patients with CF were characterized. For all isolates, rifampin (RIF) mutation frequencies and susceptibility to a range of antibiotics were determined. Of the 59 isolates, 13 (22%) were hypermutable. Whole-genome sequences were determined for all hypermutable isolates. Core genome polymorphisms were used to assess genetic relatedness of the isolates, both to each other and to a sample of previously characterized P. aeruginosa strains. Phylogenetic analyses showed that the hypermutators were from divergent lineages and that hypermutator phenotype was mostly the result of mutations in mutL or, less commonly, in mutS. Hypermutable isolates also contained a range of mutations that are likely associated with adaptation of P. aeruginosa to the CF lung environment. Multidrug resistance was more prevalent in hypermutable than nonhypermutable isolates (38% versus 22%). This study revealed that hypermutable P. aeruginosa strains are common among isolates from patients with CF in Australia and are implicated in the emergence of antibiotic resistance.

KW - Antibiotic resistance

KW - Cystic fibrosis

KW - Hypermutation

KW - Multidrug resistance

KW - Pseudomonas aeruginosa

KW - Whole-genome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85063650436&partnerID=8YFLogxK

U2 - 10.1128/AAC.02538-18

DO - 10.1128/AAC.02538-18

M3 - Article

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 1098-6596

IS - 4

M1 - e02538-18

ER -